Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., and Bayer HealthCare, of Leverkusen, Germany, announced that Bayer HealthCare submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Regeneron and Bayer HealthCare are collaborating on the global development of VEGF Trap-Eye for the treatment of wet AMD, central retinal vein occlusion, diabetic macular edema and myopic choroidal neovascularization.